Rare diseases
Investigational molecules
Locations
IOMX-0675 is an investigational monoclonal immunoglobulin G1 (IgG1) antibody.[2] It is a protein-based substance developed by IOMX Therapeutics AG.[1] The substance has no marketing authorisation in the product records, meaning it is not yet an approved medicine.[1] It is classified in the therapeutic area of neoplasms, which are abnormal growths of tissue that can be cancerous.[1]
IOMX-0675 targets two receptors called LILRB1 (also known as ILT2) and LILRB2 (also known as ILT4).[2] These receptors belong to the leukocyte immunoglobulin-like receptor (LILR) family and play a key role in tumor immune evasion, which is the ability of cancer cells to hide from the immune system.[2] LILRB1 and LILRB2 are highly expressed on tumor-infiltrating myeloid cells, a type of immune cell found inside tumors, with LILRB1 also found on lymphoid cells.[2] By blocking these receptors, IOMX-0675 is designed to reprogram immunosuppressive macrophages, restoring the activity of immune cells against the tumor.[2]
IOMX-0675 is given as an intravenous infusion, meaning it is delivered directly into a vein over a period of time.[1] In the current trial, it is administered at a dose of 1800 mg.[1]
One Phase 1 trial is currently authorised for IOMX-0675.[1] The trial, called LIMNOS, enrolls 110 participants with advanced or metastatic solid tumors that have already been treated.[1] It tests IOMX-0675 alone and in combination with pembrolizumab, an approved immunotherapy.[1] The primary goal is to identify the recommended Phase 2 dose (RP2D) of IOMX-0675, both as a single agent and in combination with pembrolizumab.[1] Researchers also measure dose-limiting toxicities, treatment-related adverse events, and pharmacokinetic parameters such as how much of the drug stays in the blood over time (AUC) and its half-life (t½).[1] The trial also evaluates maximum receptor occupancy and biomarker activity.[1]
The available sources do not provide a detailed list of side effects for IOMX-0675. The Phase 1 trial is designed to assess the type, incidence, and severity of treatment-related adverse events according to the NCI CTCAE version 5.0, a standard scale for reporting side effects in cancer trials.[1]
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
